Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC: Preoperative Infigratinib in Intrahepatic Cholangiocarcinoma
NCT05514912Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Mar 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of infigratinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Emory University. Planned start Mar 2024; status: withdrawn.
02
Drugs
infigratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05514912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514912.